Share Price and Basic Stock Data
Last Updated: October 10, 2025, 10:49 pm
PEG Ratio | 0.00 |
---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Nectar Lifescience Ltd, a pharmaceutical company, operates in a competitive market with a current share price of ₹14.6 and a market capitalization of ₹328 Cr. Analyzing the quarterly and annual sales trends, the company has shown a decline in operating profit margin (OPM) to -22%. Despite this, the net profit stands at -₹114 Cr, indicating a challenging financial period. Expenses seem to be impacting profitability, requiring a closer look at cost management strategies.
Profitability and Efficiency Metrics
With a return on equity (ROE) of 11.2% and return on capital employed (ROCE) at 5.36%, Nectar Lifescience’s efficiency metrics are moderate. The interest coverage ratio (ICR) of 1.91x suggests a healthy ability to service debt. However, the negative OPM and low ROCE indicate potential strain on profitability and capital utilization. The cash conversion cycle (CCC) of 143 days warrants attention to working capital management for improved efficiency.
Balance Sheet Strength and Financial Ratios
The company’s reserves amount to ₹934 Cr, while borrowings stand at ₹582 Cr, indicating a substantial reliance on debt financing. The price-to-book value (P/BV) ratio at 0.63x suggests the stock may be undervalued. However, the high level of borrowings raises concerns about leverage and liquidity. Monitoring debt-equity ratios and working capital health will be crucial for maintaining financial stability.
Shareholding Pattern and Investor Confidence
Promoters hold a significant stake of 44.53%, signaling confidence in the company’s prospects. Foreign institutional investors (FIIs) and domestic institutional investors (DIIs) have minimal holdings at 0.82% and 0.19%, respectively. The public holds the majority share at 54.45%, reflecting retail investor participation. Changes in shareholding patterns can influence market perception and valuation, highlighting the need for consistent investor confidence.
Outlook, Risks, and Final Insight
Looking ahead, Nectar Lifescience may benefit from diversification and innovation as key growth drivers. However, risks such as regulatory challenges and intense competition could impact future performance. Strengthening operational efficiency, reducing debt levels, and enhancing investor communication are essential for sustainable growth. In conclusion, a balanced approach to risk management and strategic planning will be crucial for navigating the dynamic pharmaceutical industry landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Nectar Lifescience Ltd
Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
---|---|---|---|---|---|---|---|---|---|
Lactose (India) Ltd | 152 Cr. | 121 | 247/84.3 | 34.6 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
MPS Pharmaa Ltd | 3.98 Cr. | 2.08 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
Gujarat Themis Biosyn Ltd | 4,528 Cr. | 415 | 434/192 | 102 | 22.8 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
Gujarat Terce Laboratories Ltd | 31.3 Cr. | 42.2 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
Gujarat Inject (Kerala) Ltd | 29.3 Cr. | 20.0 | 29.1/17.0 | 30.6 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
Industry Average | 19,005.64 Cr | 1,173.77 | 51.08 | 192.71 | 0.33% | 16.15% | 14.90% | 6.18 |
Quarterly Result
Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 403 | 389 | 344 | 389 | 394 | 398 | 452 | 441 | 359 | 428 | 455 | 431 | 281 |
Expenses | 361 | 396 | 343 | 371 | 359 | 371 | 410 | 393 | 319 | 385 | 410 | 585 | 343 |
Operating Profit | 42 | -7 | 1 | 18 | 36 | 27 | 42 | 48 | 40 | 43 | 45 | -154 | -62 |
OPM % | 10% | -2% | 0% | 5% | 9% | 7% | 9% | 11% | 11% | 10% | 10% | -36% | -22% |
Other Income | 0 | 11 | 13 | 18 | 0 | 11 | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
Interest | 21 | 21 | 17 | 20 | 18 | 21 | 25 | 24 | 20 | 20 | 17 | 18 | 19 |
Depreciation | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 16 | 16 | 16 | 17 |
Profit before tax | 6 | -32 | -18 | 2 | 3 | 2 | 2 | 11 | 5 | 9 | 13 | -188 | -97 |
Tax % | 36% | -31% | -47% | -145% | 41% | 38% | 36% | 95% | 40% | 35% | 38% | -31% | -35% |
Net Profit | 4 | -22 | -9 | 4 | 2 | 1 | 2 | 1 | 3 | 6 | 8 | -130 | -63 |
EPS in Rs | 0.17 | -1.00 | -0.41 | 0.16 | 0.08 | 0.05 | 0.07 | 0.03 | 0.13 | 0.25 | 0.35 | -5.80 | -2.82 |
Last Updated: August 20, 2025, 6:20 am
Below is a detailed analysis of the quarterly data for Nectar Lifescience Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 281.00 Cr.. The value appears to be declining and may need further review. It has decreased from 431.00 Cr. (Mar 2025) to 281.00 Cr., marking a decrease of 150.00 Cr..
- For Expenses, as of Jun 2025, the value is 343.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 585.00 Cr. (Mar 2025) to 343.00 Cr., marking a decrease of 242.00 Cr..
- For Operating Profit, as of Jun 2025, the value is -62.00 Cr.. The value appears strong and on an upward trend. It has increased from -154.00 Cr. (Mar 2025) to -62.00 Cr., marking an increase of 92.00 Cr..
- For OPM %, as of Jun 2025, the value is -22.00%. The value appears strong and on an upward trend. It has increased from -36.00% (Mar 2025) to -22.00%, marking an increase of 14.00%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Interest, as of Jun 2025, the value is 19.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 18.00 Cr. (Mar 2025) to 19.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 17.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 16.00 Cr. (Mar 2025) to 17.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -97.00 Cr.. The value appears strong and on an upward trend. It has increased from -188.00 Cr. (Mar 2025) to -97.00 Cr., marking an increase of 91.00 Cr..
- For Tax %, as of Jun 2025, the value is -35.00%. The value appears to be improving (decreasing) as expected. It has decreased from -31.00% (Mar 2025) to -35.00%, marking a decrease of 4.00%.
- For Net Profit, as of Jun 2025, the value is -63.00 Cr.. The value appears strong and on an upward trend. It has increased from -130.00 Cr. (Mar 2025) to -63.00 Cr., marking an increase of 67.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -2.82. The value appears strong and on an upward trend. It has increased from -5.80 (Mar 2025) to -2.82, marking an increase of 2.98.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: July 22, 2025, 3:19 pm
Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 1,634 | 1,638 | 1,674 | 1,635 | 1,874 | 2,779 | 2,363 | 1,541 | 1,665 | 1,520 | 1,682 | 1,673 |
Expenses | 1,345 | 1,371 | 1,436 | 1,411 | 1,638 | 2,514 | 2,143 | 1,432 | 1,507 | 1,467 | 1,530 | 1,700 |
Operating Profit | 289 | 267 | 239 | 224 | 236 | 264 | 220 | 109 | 159 | 53 | 152 | -26 |
OPM % | 18% | 16% | 14% | 14% | 13% | 10% | 9% | 7% | 10% | 3% | 9% | -2% |
Other Income | 12 | 20 | 6 | 23 | 6 | 6 | 4 | -22 | 11 | 43 | 15 | 2 |
Interest | 138 | 126 | 123 | 117 | 115 | 148 | 126 | 112 | 79 | 79 | 87 | 75 |
Depreciation | 84 | 77 | 57 | 62 | 64 | 63 | 61 | 60 | 57 | 59 | 61 | 62 |
Profit before tax | 78 | 85 | 64 | 67 | 63 | 59 | 37 | -85 | 34 | -42 | 18 | -162 |
Tax % | 21% | 22% | 15% | 18% | 17% | 19% | 15% | -14% | 26% | -43% | 73% | -30% |
Net Profit | 62 | 66 | 54 | 55 | 52 | 48 | 32 | -73 | 25 | -24 | 5 | -114 |
EPS in Rs | 2.77 | 2.95 | 2.42 | 2.47 | 2.33 | 2.12 | 1.42 | -3.27 | 1.12 | -1.08 | 0.22 | -5.07 |
Dividend Payout % | 4% | 3% | 4% | 2% | 2% | 2% | 4% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
---|---|---|---|---|---|---|---|---|---|---|---|
YoY Net Profit Growth (%) | 6.45% | -18.18% | 1.85% | -5.45% | -7.69% | -33.33% | -328.12% | 134.25% | -196.00% | 120.83% | -2380.00% |
Change in YoY Net Profit Growth (%) | 0.00% | -24.63% | 20.03% | -7.31% | -2.24% | -25.64% | -294.79% | 462.37% | -330.25% | 316.83% | -2500.83% |
Nectar Lifescience Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
Compounded Sales Growth | |
---|---|
10 Years: | 0% |
5 Years: | -7% |
3 Years: | 0% |
TTM: | -3% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -3025% |
Stock Price CAGR | |
---|---|
10 Years: | -8% |
5 Years: | -7% |
3 Years: | -14% |
1 Year: | -69% |
Return on Equity | |
---|---|
10 Years: | 0% |
5 Years: | -4% |
3 Years: | -6% |
Last Year: | -11% |
Last Updated: September 5, 2025, 11:35 am
Balance Sheet
Last Updated: July 25, 2025, 2:41 pm
Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 |
Reserves | 905 | 936 | 932 | 984 | 1,036 | 1,083 | 1,114 | 1,040 | 1,065 | 1,042 | 1,047 | 934 |
Borrowings | 858 | 925 | 962 | 878 | 955 | 903 | 779 | 903 | 860 | 754 | 636 | 582 |
Other Liabilities | 609 | 628 | 640 | 696 | 710 | 696 | 718 | 423 | 443 | 371 | 486 | 509 |
Total Liabilities | 2,394 | 2,510 | 2,556 | 2,581 | 2,724 | 2,705 | 2,633 | 2,388 | 2,391 | 2,189 | 2,191 | 2,047 |
Fixed Assets | 948 | 934 | 906 | 881 | 852 | 825 | 785 | 772 | 723 | 662 | 643 | 633 |
CWIP | 122 | 91 | 99 | 102 | 100 | 100 | 115 | 99 | 85 | 78 | 66 | 57 |
Investments | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
Other Assets | 1,324 | 1,485 | 1,551 | 1,597 | 1,771 | 1,780 | 1,733 | 1,517 | 1,582 | 1,449 | 1,482 | 1,357 |
Total Assets | 2,394 | 2,510 | 2,556 | 2,581 | 2,724 | 2,705 | 2,633 | 2,388 | 2,391 | 2,189 | 2,191 | 2,047 |
Below is a detailed analysis of the balance sheet data for Nectar Lifescience Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 22.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 22.00 Cr..
- For Reserves, as of Mar 2025, the value is 934.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,047.00 Cr. (Mar 2024) to 934.00 Cr., marking a decrease of 113.00 Cr..
- For Borrowings, as of Mar 2025, the value is 582.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 636.00 Cr. (Mar 2024) to 582.00 Cr., marking a decrease of 54.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 509.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 486.00 Cr. (Mar 2024) to 509.00 Cr., marking an increase of 23.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 2,047.00 Cr.. The value appears to be improving (decreasing). It has decreased from 2,191.00 Cr. (Mar 2024) to 2,047.00 Cr., marking a decrease of 144.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 633.00 Cr.. The value appears to be declining and may need further review. It has decreased from 643.00 Cr. (Mar 2024) to 633.00 Cr., marking a decrease of 10.00 Cr..
- For CWIP, as of Mar 2025, the value is 57.00 Cr.. The value appears to be declining and may need further review. It has decreased from 66.00 Cr. (Mar 2024) to 57.00 Cr., marking a decrease of 9.00 Cr..
- For Investments, as of Mar 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 1.00 Cr..
- For Other Assets, as of Mar 2025, the value is 1,357.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,482.00 Cr. (Mar 2024) to 1,357.00 Cr., marking a decrease of 125.00 Cr..
- For Total Assets, as of Mar 2025, the value is 2,047.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,191.00 Cr. (Mar 2024) to 2,047.00 Cr., marking a decrease of 144.00 Cr..
Notably, the Reserves (934.00 Cr.) exceed the Borrowings (582.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow | -569.00 | -658.00 | -723.00 | -654.00 | -719.00 | -639.00 | -559.00 | -794.00 | -701.00 | -701.00 | -484.00 | -608.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 84 | 99 | 107 | 112 | 119 | 73 | 61 | 89 | 98 | 67 | 82 | 76 |
Inventory Days | 240 | 253 | 260 | 270 | 226 | 151 | 192 | 185 | 197 | 212 | 215 | 184 |
Days Payable | 139 | 146 | 154 | 167 | 142 | 80 | 104 | 108 | 112 | 100 | 127 | 117 |
Cash Conversion Cycle | 185 | 207 | 213 | 215 | 203 | 145 | 150 | 166 | 182 | 179 | 170 | 143 |
Working Capital Days | 23 | 40 | 41 | 45 | 67 | 46 | 53 | 6 | 73 | 77 | 63 | 43 |
ROCE % | 12% | 11% | 10% | 10% | 9% | 10% | 8% | 3% | 5% | -0% | 6% | -5% |
This stock is not held by any mutual fund.
Key Financial Ratios
Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
---|---|---|---|---|---|
FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Basic EPS (Rs.) | 0.22 | -1.08 | 1.12 | -3.27 | 1.42 |
Diluted EPS (Rs.) | 0.22 | -1.08 | 1.12 | -3.27 | 1.42 |
Cash EPS (Rs.) | 2.93 | 1.56 | 3.66 | -0.58 | 4.13 |
Book Value[Excl.RevalReserv]/Share (Rs.) | 47.68 | 47.47 | 48.51 | 47.36 | 50.66 |
Book Value[Incl.RevalReserv]/Share (Rs.) | 47.68 | 47.47 | 48.51 | 47.36 | 50.66 |
Revenue From Operations / Share (Rs.) | 75.10 | 67.94 | 74.42 | 68.82 | 105.52 |
PBDIT / Share (Rs.) | 7.41 | 4.29 | 7.57 | 5.03 | 9.99 |
PBIT / Share (Rs.) | 4.70 | 1.65 | 5.03 | 2.34 | 7.28 |
PBT / Share (Rs.) | 0.81 | -1.89 | 1.52 | -3.78 | 1.67 |
Net Profit / Share (Rs.) | 0.22 | -1.08 | 1.12 | -3.27 | 1.42 |
NP After MI And SOA / Share (Rs.) | 0.22 | -1.08 | 1.12 | -3.27 | 1.42 |
PBDIT Margin (%) | 9.86 | 6.31 | 10.17 | 7.31 | 9.46 |
PBIT Margin (%) | 6.25 | 2.43 | 6.76 | 3.40 | 6.90 |
PBT Margin (%) | 1.08 | -2.78 | 2.04 | -5.49 | 1.58 |
Net Profit Margin (%) | 0.29 | -1.58 | 1.50 | -4.74 | 1.34 |
NP After MI And SOA Margin (%) | 0.29 | -1.58 | 1.50 | -4.74 | 1.34 |
Return on Networth / Equity (%) | 0.46 | -2.27 | 2.30 | -6.89 | 2.79 |
Return on Capital Employeed (%) | 8.65 | 2.85 | 8.13 | 4.09 | 11.78 |
Return On Assets (%) | 0.22 | -1.10 | 1.04 | -2.96 | 1.20 |
Long Term Debt / Equity (X) | 0.13 | 0.21 | 0.26 | 0.12 | 0.10 |
Total Debt / Equity (X) | 0.59 | 0.70 | 0.79 | 0.79 | 0.65 |
Asset Turnover Ratio (%) | 0.76 | 0.66 | 0.68 | 0.60 | 0.88 |
Current Ratio (X) | 1.50 | 1.59 | 1.56 | 1.04 | 1.29 |
Quick Ratio (X) | 0.59 | 0.62 | 0.69 | 0.54 | 0.51 |
Inventory Turnover Ratio (X) | 1.42 | 1.39 | 1.65 | 1.13 | 1.94 |
Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | -1.53 | 3.52 |
Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | -8.61 | 1.21 |
Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 101.53 | 96.48 |
Cash Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 108.61 | 98.79 |
Interest Coverage Ratio (X) | 1.91 | 1.21 | 2.16 | 1.01 | 1.78 |
Interest Coverage Ratio (Post Tax) (X) | 1.06 | 0.69 | 1.32 | 0.57 | 1.25 |
Enterprise Value (Cr.) | 1290.98 | 1091.93 | 1381.46 | 1231.83 | 941.69 |
EV / Net Operating Revenue (X) | 0.76 | 0.71 | 0.82 | 0.79 | 0.39 |
EV / EBITDA (X) | 7.77 | 11.35 | 8.13 | 10.92 | 4.20 |
MarketCap / Net Operating Revenue (X) | 0.40 | 0.23 | 0.32 | 0.27 | 0.09 |
Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 101.53 | 96.47 |
Price / BV (X) | 0.63 | 0.33 | 0.49 | 0.39 | 0.19 |
Price / Net Operating Revenue (X) | 0.40 | 0.23 | 0.32 | 0.27 | 0.09 |
EarningsYield | 0.01 | -0.06 | 0.04 | -0.17 | 0.14 |
After reviewing the key financial ratios for Nectar Lifescience Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 24, the value is 0.22. This value is below the healthy minimum of 5. It has increased from -1.08 (Mar 23) to 0.22, marking an increase of 1.30.
- For Diluted EPS (Rs.), as of Mar 24, the value is 0.22. This value is below the healthy minimum of 5. It has increased from -1.08 (Mar 23) to 0.22, marking an increase of 1.30.
- For Cash EPS (Rs.), as of Mar 24, the value is 2.93. This value is below the healthy minimum of 3. It has increased from 1.56 (Mar 23) to 2.93, marking an increase of 1.37.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 47.68. It has increased from 47.47 (Mar 23) to 47.68, marking an increase of 0.21.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 47.68. It has increased from 47.47 (Mar 23) to 47.68, marking an increase of 0.21.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 75.10. It has increased from 67.94 (Mar 23) to 75.10, marking an increase of 7.16.
- For PBDIT / Share (Rs.), as of Mar 24, the value is 7.41. This value is within the healthy range. It has increased from 4.29 (Mar 23) to 7.41, marking an increase of 3.12.
- For PBIT / Share (Rs.), as of Mar 24, the value is 4.70. This value is within the healthy range. It has increased from 1.65 (Mar 23) to 4.70, marking an increase of 3.05.
- For PBT / Share (Rs.), as of Mar 24, the value is 0.81. This value is within the healthy range. It has increased from -1.89 (Mar 23) to 0.81, marking an increase of 2.70.
- For Net Profit / Share (Rs.), as of Mar 24, the value is 0.22. This value is below the healthy minimum of 2. It has increased from -1.08 (Mar 23) to 0.22, marking an increase of 1.30.
- For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 0.22. This value is below the healthy minimum of 2. It has increased from -1.08 (Mar 23) to 0.22, marking an increase of 1.30.
- For PBDIT Margin (%), as of Mar 24, the value is 9.86. This value is below the healthy minimum of 10. It has increased from 6.31 (Mar 23) to 9.86, marking an increase of 3.55.
- For PBIT Margin (%), as of Mar 24, the value is 6.25. This value is below the healthy minimum of 10. It has increased from 2.43 (Mar 23) to 6.25, marking an increase of 3.82.
- For PBT Margin (%), as of Mar 24, the value is 1.08. This value is below the healthy minimum of 10. It has increased from -2.78 (Mar 23) to 1.08, marking an increase of 3.86.
- For Net Profit Margin (%), as of Mar 24, the value is 0.29. This value is below the healthy minimum of 5. It has increased from -1.58 (Mar 23) to 0.29, marking an increase of 1.87.
- For NP After MI And SOA Margin (%), as of Mar 24, the value is 0.29. This value is below the healthy minimum of 8. It has increased from -1.58 (Mar 23) to 0.29, marking an increase of 1.87.
- For Return on Networth / Equity (%), as of Mar 24, the value is 0.46. This value is below the healthy minimum of 15. It has increased from -2.27 (Mar 23) to 0.46, marking an increase of 2.73.
- For Return on Capital Employeed (%), as of Mar 24, the value is 8.65. This value is below the healthy minimum of 10. It has increased from 2.85 (Mar 23) to 8.65, marking an increase of 5.80.
- For Return On Assets (%), as of Mar 24, the value is 0.22. This value is below the healthy minimum of 5. It has increased from -1.10 (Mar 23) to 0.22, marking an increase of 1.32.
- For Long Term Debt / Equity (X), as of Mar 24, the value is 0.13. This value is below the healthy minimum of 0.2. It has decreased from 0.21 (Mar 23) to 0.13, marking a decrease of 0.08.
- For Total Debt / Equity (X), as of Mar 24, the value is 0.59. This value is within the healthy range. It has decreased from 0.70 (Mar 23) to 0.59, marking a decrease of 0.11.
- For Asset Turnover Ratio (%), as of Mar 24, the value is 0.76. It has increased from 0.66 (Mar 23) to 0.76, marking an increase of 0.10.
- For Current Ratio (X), as of Mar 24, the value is 1.50. This value is within the healthy range. It has decreased from 1.59 (Mar 23) to 1.50, marking a decrease of 0.09.
- For Quick Ratio (X), as of Mar 24, the value is 0.59. This value is below the healthy minimum of 1. It has decreased from 0.62 (Mar 23) to 0.59, marking a decrease of 0.03.
- For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.42. This value is below the healthy minimum of 4. It has increased from 1.39 (Mar 23) to 1.42, marking an increase of 0.03.
- For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 23) which recorded 0.00.
- For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 23) which recorded 0.00.
- For Earning Retention Ratio (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 23) which recorded 0.00.
- For Cash Earning Retention Ratio (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 23) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 24, the value is 1.91. This value is below the healthy minimum of 3. It has increased from 1.21 (Mar 23) to 1.91, marking an increase of 0.70.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 1.06. This value is below the healthy minimum of 3. It has increased from 0.69 (Mar 23) to 1.06, marking an increase of 0.37.
- For Enterprise Value (Cr.), as of Mar 24, the value is 1,290.98. It has increased from 1,091.93 (Mar 23) to 1,290.98, marking an increase of 199.05.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 0.76. This value is below the healthy minimum of 1. It has increased from 0.71 (Mar 23) to 0.76, marking an increase of 0.05.
- For EV / EBITDA (X), as of Mar 24, the value is 7.77. This value is within the healthy range. It has decreased from 11.35 (Mar 23) to 7.77, marking a decrease of 3.58.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 0.40. This value is below the healthy minimum of 1. It has increased from 0.23 (Mar 23) to 0.40, marking an increase of 0.17.
- For Retention Ratios (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 23) which recorded 0.00.
- For Price / BV (X), as of Mar 24, the value is 0.63. This value is below the healthy minimum of 1. It has increased from 0.33 (Mar 23) to 0.63, marking an increase of 0.30.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 0.40. This value is below the healthy minimum of 1. It has increased from 0.23 (Mar 23) to 0.40, marking an increase of 0.17.
- For EarningsYield, as of Mar 24, the value is 0.01. This value is below the healthy minimum of 5. It has increased from -0.06 (Mar 23) to 0.01, marking an increase of 0.07.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Strength | Weakness |
---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Nectar Lifescience Ltd:
- Net Profit Margin: 0.29%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 8.65% (Industry Average ROCE: 16.15%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0.46% (Industry Average ROE: 14.9%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.06
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.59
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 51.08)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.59
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.29%
About the Company - Qualitative Analysis
INDUSTRY | ADDRESS | CONTACT |
---|---|---|
Pharmaceuticals | Village Saidpura, Tehsil Derabassi, Mohali Punjab 140507 | cs@neclife.com http://www.neclife.com |
Management | |
---|---|
Name | Position Held |
Mr. Sanjiv Goyal | Chairman & Managing Director |
Dr. Surulichamy Senethilkumar | Director - R & D |
Dr. Indu Pal Kaur | Independent Director |
Ms. Meena Verma | Nominee Director |
Dr. Rupinder Tewari | Independent Director |
Dr. Kuldip Kumar Bhasin | Independent Director |
FAQ
What is the intrinsic value of Nectar Lifescience Ltd?
Nectar Lifescience Ltd's intrinsic value (as of 10 October 2025) is 58.40 which is 314.18% higher the current market price of 14.10, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹318 Cr. market cap, FY2025-2026 high/low of 44.9/13.0, reserves of ₹934 Cr, and liabilities of 2,047 Cr.
What is the Market Cap of Nectar Lifescience Ltd?
The Market Cap of Nectar Lifescience Ltd is 318 Cr..
What is the current Stock Price of Nectar Lifescience Ltd as on 10 October 2025?
The current stock price of Nectar Lifescience Ltd as on 10 October 2025 is 14.1.
What is the High / Low of Nectar Lifescience Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Nectar Lifescience Ltd stocks is 44.9/13.0.
What is the Stock P/E of Nectar Lifescience Ltd?
The Stock P/E of Nectar Lifescience Ltd is .
What is the Book Value of Nectar Lifescience Ltd?
The Book Value of Nectar Lifescience Ltd is 42.6.
What is the Dividend Yield of Nectar Lifescience Ltd?
The Dividend Yield of Nectar Lifescience Ltd is 0.00 %.
What is the ROCE of Nectar Lifescience Ltd?
The ROCE of Nectar Lifescience Ltd is 5.36 %.
What is the ROE of Nectar Lifescience Ltd?
The ROE of Nectar Lifescience Ltd is 11.2 %.
What is the Face Value of Nectar Lifescience Ltd?
The Face Value of Nectar Lifescience Ltd is 1.00.